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ABSTRACT 
TITLE : COMPARATIVE STUDY OF EFFICACY OF HAND FOOT 
PSORALEN ULTRAVIOLET A THERAPY VERSUS SEQUENTIAL 
THERAPY OF TOPICAL CLOBETASOL PROPIONATE WITH TOPICAL 
CALCIPOTRIOL OINTMENT IN PALMOPLANTAR PSORIASIS  
 
BACKGROUND 
                  Psoriasis is a common genetically determined chronic 
inflammatory skin disease. It is characterized by well defined erythematous plaque 
with silvery white scales. It is commonly distributed over the elbow, knee, lower 
back, nails, scalp, palms and soles. It is associated with varying periods of 
remission and relapse. Various modalities of treatment have been tried. The main 
goal of therapy is rapid control of the disease and to maintain a longer duration of 
remission. Treatment of palmoplantar psoriasis and remission maintenance is very 
difficult.   
AIM OF THE STUDY 
The aim of the study is to compare the efficacy of topical psoralen and 
ultraviolet A phototherapy with sequential therapy of topical 0.05% clobetasol 
propionate ointment and topical 0.005% calcipotriol ointment in palmoplantar 
psoriasis and to observe the adverse effects, remission maintenance and PASI 
percentage reduction of more than 50% in both groups. 
MATERIALS AND METHODS 
50 patients are included in the study. The population for the study included 
patients attending outpatient Department of Dermatology, Coimbatore Medical 
College Hospital, Coimbatore. The patients are divided into two groups, group A 
and group B. The treatment duration was 6 months and the follow up period was 6 
months. Each group has 25 patients.  
Group A patients received topical hand foot PUVA therapy with minimum 
dose of 1J/cm2 with increment dosage of 0.5J/cm2, in the frequency two times per 
week and the maximum dose of 24.5J/cm2 in some patients. Eyes were protected 
by using goggles during treatment. 
 In group B sequential therapy of calcipotriol ointment combinations given 
in three phases, in phase 1 combination of clobetasol propionate and calcipotriol 
ointment once a day application in the first month, in phase 2 clobetasol propionate 
for weekends and calcipotriol for week days once a day application in the second 
and third month, in phase 3 calcipotriol ointment once a day application in the 
fourth, fifth and sixth month. PASI score and PASI percentage reduction was 
assessed at the end of 8
th
,16
th
,24
th
 weeks. 
RESULTS 
 During treatment, 3 patients in group A and 1 patient in group B lost follow 
up. In both groups none of the patients showed complete clearance of both palms 
and plantar lesions. 
In group A out of 22 patients, 20 (90%) showed more than 50% reduction of 
PASI score. Four patients showed complete clearance of lesion in the palms. Two 
patients showed complete clearance of lesion in the soles. The average period of 
clearance of lesions was at 19 weeks. In six months follow up period 3 patients 
showed relapse after 15 weeks of average period of remission. 4 patients showed 
adverse effect like erythema and burning sensation. In group B out of 24 patients, 
all (100%) showed more than 50% reduction of PASI score. Seven patients showed 
complete clearance of lesion in the palms and five patients showed complete 
clearance of lesion in the soles. The average period of clearance of lesions was at 
20.3 weeks. In six months follow up period 2 patients showed relapse after 20 
weeks of average period of remission. 3 patients showed adverse effect like 
erythema,itching and burning sensation.  
 
 
 
CONCLUSION 
 The efficacy of topical calcipotriol ointment and steroid used in sequential 
manner is better than the topical psoralen ultraviolet A therapy. All the patients 
(100%) in calcipotriol and steroid combination group showed more than 50% 
reduction of PASI score. But in PUVA therapy group 90% of patients showed 
more than 50% reduction of PASI score. On comparing the adverse effects, 
patients on PUVA therapy group developed more adverse effects than the patients 
on calcipotriol and steroid combination group. The duration of remission 
maintenance was long in calcipotriol and steroid combination group when 
compared to PUVA therapy group. 
In our study, we arrived at the conclusion  that topical therapies used in a 
sequential manner  was more effective and it may be considered as a first line 
therapy for the treatment of patients with palmoplantar psoriasis.  
KEY WORDS: Hand Foot PUVA, calcipotriol – clobetasol combinations, PASI 
score and percentage reduction 
 
  
  
 
 
INTRODUCTION 
Psoriasis is a common genetically determined chronic 
inflammatory skin disease. It is characterized by well defined 
erythematous plaque with silvery white scales. It is commonly distributed 
over the elbow, knee, lower back, nails, scalp, palms and soles. It is 
associated with varying periods of remission and relapse. Various 
modalities of treatment have been tried. The main goal of therapy is rapid 
control of the disease and to maintain a longer duration of remission.    
 
 
 
 
 
 
 
 
  
 
                                       AIMS AND OBJECTIVES 
1. To compare the efficacy of topical psoralen and ultraviolet A 
phototherapy with sequential therapy of topical 0.05% 
clobetasol propionate ointment and topical 0.005% calcipotriol 
ointment in palmoplantar psoriasis. 
2. To observe the reduction in percentage of PASI ( psoriasis area 
and severity index ) score  above 50% in both groups. 
3. To observe the adverse effects of both treatment modalities. 
4. To observe the duration of remission after treatment, during the 
study period. 
 
 
 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
  HISTORY  
                 The Greeks divided skin disease into 3 categories of psora, 
lepra, leichen.  Lepra derived from greek word lopos (epidermis) and lepo 
(scale). ‘Lepra’ includes psoriasis, vitiligo, alopecia areata, boils, and 
eczema
 [1]
. The bibilical term ‘tsaraat’ or ‘zaraath’ includes leprosy & 
psoriasis. Hippocrates and his school classified dry scaly eruptions as 
‘lopoi’ which included psoriasis and leprosy. The first recognizable 
clinical description of psoriasis is credited to Roman sage Aureliues 
Cornelius Celsus (25 BC-45AD) 
[2]
. ‘Psora’ means desquamation or itch 
and it was first used by Galen (133-200AD). He described psoriasis as a 
pruritic scaly skin disease of the eyelids and scrotum. Robert Willan gave 
accurate description of psoriasis in 1809, but he did not differentiate it 
from leprosy. He also described it as ‘lepra vulgaris’. Ferdinand Von 
Hebra differentiated psoriasis and leprosy clinically in 1841. Heinrich 
Koebner first described Koebner phenomenon. 
 
 
 
  
EPIDEMIOLOGY  
             The prevalence of psoriasis in the world is 0.1-3%. The incidence 
is 60/100000 per year. In India 0.44% to 2.8% populations are affected by 
psoriasis
[3]
. The incidence is increased in first and second degree 
relatives. Males and females are equally affected in psoriasis. A study 
from North India, Bedi et al reported male to female ratio is 2.5:1 
[4]
.
  
 
 GENETIC FACTORS  
Psoriasis is commonly associated with HLA Cw6 other 
associations include  HLA-B 13, HLA-B 17, HLA-B 37, HLA-B 16, 
HLA- B27 and the Chromosome is 6.  It is divided into two types 
according to HLA association and age 
[5]
.
    
Type 1 is associated with HLA 
Cw6 with family history and severe manifestations. The age of onset is at 
20-30 years. Type 2 is non HLA cw6 associated with absence of family 
history and mild manifestations. The age of onset is 50-60 years. 
Concordance for psoriasis is more common with monozygotic twins. 
Familial occurrence of the disease is 7-36%. Rarely it is associated with 
autoimmune diseases like vitiligo and bullous pemphigoid.  
 
 
  
TRIGGERING FACTORS  
1. Trauma: Psoriatic lesions will develop at the site of trauma in the skin. 
This is called as Koebner phenomenon.  
2. Smoking and alcohol will also exacerbate the disease. 
3. Stress:  It will exacerbate or trigger the disease in 60% of the patients. 
4. Exacerbation during winter season. 
5. Pregnancy:  In pregnancy remission may occur due to increase level of 
IL-10 in the circulation and in postpartum period disease will be 
exacerbated. 
6. Infections: Infections like streptococci and HIV will exacerbate the 
disease. 
7. Drugs: Drugs will precipitate or exacerbate the disease. The drugs 
include lithium salts, NSAIDs, anti malarials, ACE inhibitors, β 
adrenergic blocking agents and high dose estrogen therapy. 
 
PATHOGENESIS 
Psoriasis has been regarded as a T cell-driven disease for the past two 
decades
 [6, 7]
.Psoriasis is caused by abnormalities in the adaptive immune 
system and in the innate immune function of resident epidermal cells 
[8]
. 
Recently it is considered as an inflammatory epithelial disease 
[9]
.
  
  
IMMUNOPATHOGENESIS  
 Epidermis contains CD8 T cells and dermis contains mixture of 
both CD4 and CD8 T cells. The T cells are memory cells and natural 
killer cells (NK cells). Memory T cells are the majority cells, which 
express cutaneous lymphocyte associated antigen (CLA) which act as 
skin homing receptor and chemokine receptor CCR4. NK cells interact 
with CD1d on keratinocytes. So it increases the production of IFN 
gamma which contributes to additional immune mechanism. Increased 
activity of Langerhans cells and dendritic cells cause potent 
immunostimulatory capacity. Increased dermal and epidermal 
dendrocytes activate T cells. Plasmocytoid dendritic cells initiate 
psoriasis by production of IFN gamma
 [10]
. 
            Although the activated neutrophils contribute to pathogenesis, 
they are not considered to be the primary cause of psoriasis. Angiogenesis 
is increased due to overexpression of vascular endothelial growth factors 
like E-selectin and ICAM on dermal vessels in lesional skin. So it leads to 
accumulation of T lymphocytes. 
 
 
 
  
CYTOKINES AND CHEMOKINES  
            Increased level of Th1 cytokines mainly IFN gamma and IL-2, 
decreased level of anti inflammatory cytokines IL-10 and increased 
production of IL-12, IL-23, and IL-15 contibute to the disease. IL-23 
stimulates Th cells to release IL-22. This mechanism causes keratinocyte 
overproliferation and dermal inflammation. 
INNATE IMMUNITY  
           Innate immune cytokines are upregulated due to overactivity of 
dendritic cells, NK cells, neutrophils and epidermal keratinocytes.  
DIFFERENT CLINICAL TYPES OF PSORIASIS  
1. Chronic plaque psoriasis 
2. Guttate psoriasis 
3. Arthropathic psoriasis 
4. Pustular psoriasis 
5. Erythrodermic psoriasis 
6. Unstable psoriasis 
7. Regional variations in psoriasis  
                 Scalp 
                 Nails 
                 Palms and sole 
  
                 Face 
                 Flexures 
                 Scrotum 
                 Napkin area 
8. Special variants  
                   Rupioid 
                   Elephantine 
                   Ostraceous psoriasis 
9. Atypical variants 
[11, 12]
 – seborrhoeic psoriasis, mucosal lesions, 
ocular lesions, linear and zonal lesions, digital and interdigital, 
verrucous lesions, follicular form and lichenoid variety. 
 
PALMOPLANTAR PSORIASIS  
Palmoplantar psoriasis that accounts for 3% - 4% of all psoriasis 
cases produces significant functional and social disability 
[13]
. Reduction 
of pain and improvement in the function of limbs are more important 
therapeutic goals than complete clearance. Psoriasis in the soles will 
present as discrete scaly plaques, diffuse hyperkeratotic plaques or 
erythematous plaques. Sometimes fissures may be present. Nowadays, 
psoriasis is considered as a heterogeneous disease and many authors 
define palmoplantar pustulosis as a separate clinical entity with its genetic 
  
predisposition, course, and therapeutic management which differ from 
psoriasis itself 
[14]
.
 
 
CLINICAL VARIANTS OF PALMOPLANTAR PSORIASIS 
ACCORDING TO NOBEL CLASSIFICATION 
[19]
 
1. Sharply demarcated erythematous patches and covered by adherent 
psoriatic scales. 
2. Diffuse mild hyperkeratosis with scales. 
3. Very thick hyperkeratotic layer resembling hereditary type of 
palmoplantar keratoderma 
4. Diffuse erythema. 
NOBEL CATEGORIZATION OF PALMOPLANTAR PSORIASIS
 [19]
 
Mild - Noble type 1 and 2 
Moderate - Noble type 3  
Severe - Noble type 4 
DIFFERENTIAL DIAGNOSIS  
1. Chronic allergic contact dermatitis 
2. Tinea pedis 
3.  Palmoplantar keratoderma 
4. Porokeratosis  
  
PASI score  
      It was first described in 1978. The severity of psoriasis is assessed by 
psoriasis area severity index.  According to Carlin et al PASI score 
reduction of 50% corresponds to a clinically significant endpoint in 
assessment of palmoplantar psoriasis 
[15-18]
.
  
INVESTIGATIONS  
Psoriasis is usually diagnosed clinically but rarely requires biopsy 
for confirmation.  
The histopathological findings are  
Hyperkeratosis 
Parakeratosis 
Munromicro abscess in the stratum corneum 
Thin or absent granular layer 
Supra papillary thinning (part of stratum malphigii) with presence of 
spongiform pustule of Kogoj. 
Regular elongation of rete ridges and thickening of their lower portion 
showing club shape (camel foot appearance). 
  
Dilated tortuous capillaries in the papillae and perivascular infiltration of 
mononuclear cells. 
TREATMENT OF PALMOPLANTAR PSORIASIS  
                    In 19
th
 century arsenic and ammoniated mercury were used 
to treat psoriasis 
[20-23]
. Reassurance and emotional support is needed 
before starting treatment. Avoidance of aggravating factors is the first 
step in the management. 
                 Topical therapy is the first line of treatment. Systemic therapy 
is advised if the disease is refractory to topical therapy. 
MULTI-MODALITY THERAPEUTIC STRATEGIES  
a) Combination therapy: To reduce toxicity, the two therapeutic agents 
are given simultaneously. After attaining therapeutic response the 
accelerator is tapered and maintenance agent is continued. 
b) Rotational therapy 
[24]
: To prevent cumulative effect, the drugs are 
given rotationally. 
c) Sequential therapy 
[25]
: It has three steps. 1. Clearing or quick fix phase               
2. Transitional phase  3. Maintenance phase  
                 one example is using topical clobetasol propionate and 
calcipotriol twice a day in phase one, followed by transitional phase in 
  
which the steroid is used on weekends and calcipotriol on weekdays and 
finally a maintenance phase, in which calcipotriol is continued as long as 
required with gradual tapering off. 
TOPICALLY AVAILABLE TREATMENT FOR 
PALMOPLANTAR PSORIASIS  
1. Salicylic acid (2-10%) 
2. Coal tar (1-5%) 
3. Anthralin 
4. Topical corticosteroids 
5. Vitamin D analogues 
a) Calcitriol 
b) Calcipotriol 
c) Tacalcitol 
d) Maxacalcitol 
6. Topical psoralen with UVA 
7. Topical Retinoid (Tazarotene) 
8. Emollients 
9. Topical cytostatic therapy 
a) Mechlorethamine (Nitrogen mustard) 
b) Thiotepa 
  
c) 5 - Flurouracil 
d) Lomustine 
e) Methotrexate gel (1%) 
[26]
 
12. Topical allantoin 
AVAILABLE SYSTEMIC AGENTS  
1. Methotrexate 
2. Cyclosporine 
3. Retinoids 
4. Sulfasalazine 
5. Fumaric acid esters 
6. Azathioprine 
7. Hydroxyurea 
8. Mycophenolate mofetil 
9. Leflunomide 
10.6 Thioguanine 
 
 
  
AVAILABLE BIOLOGIC AGENTS   
          FDA approved a number of biologic agents in january 2003. They 
include for the treatment of palmoplantar psoriasis. They are 
1. Alefacept 
2. Efalizumab 
3. Etanercept 
4. Infliximab 
5. Adalimumab 
6. Ustekinumab 
OTHERS 
1. Occlusive agents 
2. Photodynamic therapy 
3. Monochromatic excimer laser 
4. Radiotherapy 
5. Pulsed dye laser 
 
  
  
TREATMENT FOR RECALCITRANT PALMO PLANTAR PSORIASIS  
      Photodynamic therapy, methotrexate, acitretin, cyclosporine are the 
available therapies for recalcitrant palmoplantar psoriasis. 
LET US DISCUSS ABOUT THE TOPICAL THERAPIES ARE 
USED IN PALMOPLANTAR PSORIASIS 
SALICYLIC ACID   
                  Available formulations are Creams, Ointments, Shampoos, 
Collodion - based paints and gels, Paste (Lassars paste contains salicylic 
acid and zinc oxide). It deactivates calcipotriol so it should not be 
combined with it. It should not be combined with UVB also as it blocks 
its penetration 
[27]
.The available strength is 2 – 10%. 
COAL TAR  
Coal tars are produced by primary condensation of carbonized coal 
[28]
. It has antibacterial, antifungal, anti inflammatory and anti pruritic 
effect 
[29]
. Since it is messy it is not acceptable to patients. It has been 
found useful with combination of topical corticosteroid. Crude coal tar 
LCD (liquor carbonis detergens) is also useful.  
  Available formulations are cream, lotions, ointment, gel, 
shampoo,soap and alcohol extract. The contraindications are pre existing 
  
folliculitis, acne, pregnancy and lactation. The available strength is 1 – 
5%. 
DITHRANOL (0.05%-4%) 
It has antiproliferative effect and not suitable for psoriasis over 
head, neck, flexures and genitalia. The total contact period is 10 minutes / 
day 
[30-33]
.
 
The available preparations are paste, cream, ointment, stick. It 
can be combined with topical steroids, PUVA, narrowband UVB, coal 
tar, calcipotriol, tazarotene, oral cyclosporine and oral retinoids.  
VITAMIN A ANALOGUES  
            Tazarotene (acetylene retinoid) is a third generation retinoid. It is 
otherwise called as arotenoid and is a prodrug of tazarotenic acid. 
Available formulations are cream and gel (0.05 and 0.1% gel). It is 
applied once daily for three months. The maximum treated area is 10-
20%. 
VITAMIN D3 ANALOGUES 
         Since 1990 vitamin D3 is used as a topical agent. Vitamin D 
receptors present in keratinocytes, Langerhans cells, melanocytes, 
fibroblasts, endothelial cells, normal breast tissue and breast tumor cells. 
It inhibits epidermal proliferation, induces keratinocyte proliferation. Due 
  
to fewer side effects and good therapeutic efficacy it is the one of best 
therapeutic agent for psoriasis 
[34]
. There are four analogues in widespread 
use; they are calcipotriol, calcitriol, tacalcitol, maxacalcitol. 
 Mechanism of action   
           Vitamin D binds with RXR- alpha, which in turn binds with vit D 
response elements of DNA. It inhibits IL-2, IL-6 production and blocks 
transcription of IFN- gamma, GM-CSF, also inhibits cytotoxic T cells, 
NK cells activity. It shifts the Th1 cytokine to Th2. It increases IL– 10 
and decreases IL-8. 
TOPICAL CALCIPOTRIOL  
    The effect of the drug is slower than topical corticosteroids (TCS). To 
attain maximal effect 8-10 weeks of treatment is needed. For rapid 
activity TCS is combined with topical calcipotriol.  It should not be 
combined with acid products because it is inactivated especially by 
salicylic acid and hydrocortisone -17-valerate 
[35]
. It is a synthetic vitamin 
D derivative which acts by binding to vitamin D receptor. Occurrence of 
hypercalcemia is rare. It induces terminal differentiation and 
simultaneous inhibition of proliferation of epidermal keratinocytes. 
Therefore used in disorders characterized by hyperkeratosis, acanthosis, 
parakeratosis  and epidermal hyperproliferation. The maximum quantity 
 of maintenance dose is 
concentration is 50 micro
namely quick - fix phase, transitionsl phase
Monitoring of serum or urinary calcium is no
psoriasis. Twice daily clobetasol propionate foam on weekends with 
twice daily calcipotriol on weekdays led to 92% clearance of psoriatic 
trunk lesions compared to only 62% with calcipotriol and vehicle after 6 
months of treatment 
lotion. 
Chemical structure of Calcipotriol 
26, 27-cyclo-vitamin D3
 22, 23- double bond
Transposition of the 25
     It is not applied prior to
Recently a combination of calcipotriol with super potent topical 
 
100g /week to prevent hypercalcemia 
gram/gm. Treatment is given in
 and maintenance
t required in localized 
[37]
. The available formulations are ointment, cream, 
 
 
 
 
-OH to the 24 position 
 PUVA because it is inactivated by UVA. 
[36]
. The 
 three phases 
 phase. 
  
corticosteroids was used for treatment of psoriasis. The response was 
rapid and it reduced the irritation 
[38]
. 
Calcipotriol acts on specific markers of epidermal proliferation (ki 67) 
and differentiation (keratin 10) and is more selective on T cell subset. 
This leads to major reduction of CD45RO & CD8 cells. 
Corticosteroids increase keratin 10 at the epidermal level without 
significant effect on ki-67 and reduce NK-T cell receptor.  
INDICATIONS  
FDA approved for Psoriasis 
 1. Mild to moderate type (monotherapy or combination) 
 2. Severe type (combination) 
OTHER DERMATOLOGICAL USES 
DISORDERS OF KERATINIZATION 
[42]
  
1. X linked recessive Icthyosis 
2. Lamellar Ichthyosis 
3. Epidermolytic hyperkeratosis 
4. Sjogren Larsson syndrome 
  
AUTO IMMUNE DISORDERS  
1. Morphoea 
2. Vitiligo 
NEOPLASTIC DERMATOSES  
1. Cutaneous T cell lymphoma 
2. Cutaneous metastatic breast cancer 
MISCELLANEOUS DERMATOSES  
1. Acanthosis nigricans 
2. Confluent & reticulated papillomatosis 
3. Disseminated superficial actinic porokeratosis 
4. Erythema annulare centrifugum 
5. Grover’s disease 
6. Inflammatory linear verrucous epidermal nevus 
7. Keratosis lichenoides chronica 
8. Pityriasis rubra pilaris 
9. Prurigo nodularis 
  
10. Seborrhoeic dermatitis 
CONTRAINDICATIONS  
         There are no absolute contraindications for calcipotriol. The relative 
contraindications are conditions causing hypercalcemia, abnormality in 
bone or calcium metabolism, renal insufficiency, allergy to vitamin D3 
analogues, pregnancy & lactation. 
PREGNANCY – category C 
SIDE EFFECTS  
         The side effects are local irritation in 20% of patients, itching and 
redness 
TOPICAL CORTICOSTEROIDS   
             Since 1950, topical corticosteroid is the most useful therapy. In 
1950 Nobel Prize was given to Henoch, Kendall and Reichstein for the 
development of cortisone.  Steroids have been used for 6-8 wks for palmo 
plantar psoriasis. 
            Pharmacokinetics action depends on the structure of molecule, 
vehicle and application site. TCS preparations are evaluated with the 
vasoconstriction assay. 
  
CLASSIFICATION OF TOPICAL CORTICOSTEROIDS 
[43]
   
CLASS І super potent: 
     Clobetasol propionate gel, ointment,cream  and lotion 0.05% 
     Betamethasone  dipropionate gel* and ointment* 0.05% 
     Diflorasone diacetate ointment* 0.05% 
     Fluocinonide cream 0.1% 
     Flurandrenolide tape 4µg/cm2 
     Halobetasol propionate ointment and cream 0.05% 
CLASS ІІ High potent: 
     Amcinonide ointment 0.1% 
     Betamethasone dipropionate cream* and ointment 0.05% 
     Clobetasol propionate solution (scalp application) 0.05% 
      Desoximethasone ointment , cream 0.25% and gel 0.05% 
      Diflorasone diacetate ointment and cream* 0.05% 
      Fluocinonide gel, ointment, cream and solution 0.05% 
      Halocinonide ointment and cream 0.1% 
  
      Mometasone furoate ointment 0.1% 
 CLASS ІІІ High Potent:  
      Amcinonide cream and lotion 0.1% 
      Betamethasone dipropionate cream and lotion 0.05% 
      Betamethasone valerate ointment 0.1% 
      Desoximethasone cream 0.05% 
      Diflorasone diacetate cream 0.05% 
      Fluticasone propionate ointment 0.005% 
      Triamcinolone acetonide ointment 0.1% and cream 0.5% 
 CLASS ІV Medium potent: 
     Betamethasone valerate foam 0.12% 
      Fluocinolone acetonide ointment 0.025% 
      Flurandrenolide ointment 0.05% 
      Hydrocortisone valerate ointment 0.2%  
      Momentasone furoate cream and lotion 0.1% 
      Triamcinolone acetonide ointment and cream 0.1% 
  
 CLASS V Medium potent: 
      Betamethasone dipropionate lotion 0.05% 
      Betamethasone valerate cream and lotion 0.1% 
      Clocortilone pivalate cream 0.1% 
      Fluocinolone acetonide cream 0.025% and oil 0.01% 
      Fluocinolone propionate cream and lotion 0.05% 
      Flurandrenolide cream and lotion 0.05% 
      Hydrocortisone valerate cream 0.2% 
      Hydrocortisone probutate cream 0.1% 
      Prednicarbate ointment  and cream 0.1% 
      Triamcinolone acetonide lotion 0.1% 
 CLASS VІ Low potent: 
      Aclomethasone dipropionate ointment and cream 0.05% 
      Triamcinolone acetonide cream 0.1% 
      Betamethasone valerate lotion 0.1% 
      Desonide gel,ointment, cream, lotion and foam  0.05% 
      Fluocinolone acetonide cream 0.01% and solution 0.05% 
      Triamcinolone acetonide cream and lotion 0.025% 
  
CLASS VII  Low potency: 
      Topicals with hydrocortisone, dexamethasone and prednisolone 
*Optimized vehicle 
STRUCTURE OF TOPICAL CORTICOSTEROID 
                  Hydrocortisone is the backbone of the topical corticosteroid 
molecule. Hydrocortisone is the parent compound of modern 
glucocorticosteroid derivatives. In 1952, Sulzberger used topical 
hydrocortisone for eczematous eruption for the first time. It has 
cyclopentanoperhydrophenanthrene nucleus with high glucorticosteroid 
and low mineralocorticoid activity 
[44]
. 
                Enzymes in the epidermis cause deesterification of topical 
corticosteroid into active metabolite. Halogenation at the 21 portion 
inhibits de esterification  at the 17 portion and increase the potency. 
Halogenation of the 9 th position leads to high glucocorticoid activity.  
 
 
 
 
  
STRUCTURE OF CLOBETASOL PROPIONATE   
               Vasoconstriction potency rating is class I superpotent 0.05% 
 Functional groups   
C1, 2: double bond 
C9: fluorine 
C16: methyl 
C17: ester 
C21: chlorine 
TOPICAL CORTICOSTEROIDS MECHANISM OF ACTION 
Corticosteroids are therapeutic by virtue of their anti-inflammatory, 
antiproliferative, immuosuppressive and vasoconstrictive properties. The 
action is mediated by its binding to the glucocorticoid receptor in the 
cytoplasm of the cell. This complex binds to acceptor sites on DNA and 
after that gene regulation and transcription of mRNA occur 
[45-47]
. 
  
Anti-inflammatory effects  
                 Vascular sensitivity is reduced by   preventing the release of 
prostaglandins, platelet activating factor and inhibition of mast cell 
sensitization which cause histamine release. Vascular permeability is 
decreased by induction of anti inflammatory proteins like lipocortin, 
vasocortin, vasoregulin and hence decrease the release of arachidonic 
acid, prostaglandins. It decreases the production of inflammatory 
mediators IL-1α, IL-1β, INF- gamma, TNF, IL-2 and GM-CSF. 
Antiproliferative and atrophogenic effects  
                    Corticosteroids reduce the thickness of epidermal layer, 
reduce mitoses and growth factors. In the dermis it causes atrophy by 
reduced dermal volume, hypoactive fibroblasts and fragility of dermal 
vessels. 
INDICATIONS  
Dermatitis and papulosquamous disorders 
1. Atopic dermatitis 
2.  Diaper dermatitis 
3.  Dyshidrotic eczema 
4.  Erythroderma 
  
5.  Lichen planus 
6.  Lichen simplex chronicus  
7. Nummular dermatitis 
8.  Pityriasis rosea 
9.  Palmoplantar, plaque and intertriginous type of psoriasis, 
10.  Seborrhoeic dermatitis 
Bullous dermatoses 
1. Bullous pemphigoid 
2. Cicatricial pemphigoid 
3. Epidermolysis bullosa acquisita 
4. Pemphigus foliaceous 
           5.  Pemphigoid  gestationis 
Connective tissue disease 
1. Lupus erythematosus 
2. Dermatomyositis 
Neutrophilic dermatoses 
1. Pyoderma gangrenosum  
2. Behcets disease 
 
  
OTHERS  
1. Alopecia areata 
2. Acne keloidalis nuchae 
3. Cutaneous T cell lymphoma 
 4. Granuloma annulare 
5. Jessners lymphocytic infiltrare  
6. Lichen plano pilaris  
7. Lichen sclerosus et atropicus 
8.  Morphoea   
9. Vitiligo 
10. Wells syndrome 
CONTRAINDICATIONS  
ABSOLUTE 
Known hypersensitivity to topical corticosteroids 
RELATIVE  
Bacterial, viral, fungal, mycobacterial infections , infestations and 
ulcerations 
  
ADVERSE EFFECTS  
A) Local side effects are hypopigmentation, wrinkled skin, pseudo scar, 
striae , purpura, steroid addiction, glaucoma, allergic contact dermatitis, 
irritant contact dermatitis, tachyphylaxis, folliculitis, miliaria, perioral 
dermatitis, rosacea, acneiform eruptions, crusted scabies, telangiectasia, 
erythema, purpura. 
B) Systemic side effects are suppression of hypothalamic pituitary 
adrenal axis, iatrogenic cushing syndrome, growth retardation in infants 
and  children 
AVAILABLE PREPARATIONS  
            Ointment, cream, gel, lotion, solution,foams,sprays and tapes 
[48]
. 
Ointment form has the highest efficacy. The optimal improvement within 
2 weeks and 74% of  patients remained in remission. 
           Topical Corticosteroids are frequently used in combinations with 
topical vitamin D analogues, calcineurin inhibitors, coal tar, anthralin, 
tazarotene, systemic drugs and photo therapy. Combination of 
corticosteroids with topical vitamin D analogue is more potent. 
 
 
  
DOSE  
The recommended dose for adult is less than 45gm/week and for 
infants & children is less than15gm/week. 
In this combination regimen of calcipotriol and steroid, calcipotriol 
is well tolerated and the irritation of vitamin D derivative is reduced 
[39]
. 
The immunosuppressive effect of calcipotriol on T helper cells are 
augmented by corticosteroids 
[40]
.The combination of clobetasol and 
calcipotriol ointment is significantly more effective than monotherapy for 
short-term treatment. Weekday calcipotriol plus weekend pulse clobetasol 
ointment shows a consistent trend toward greater maintenance of 
remission 
[37, 41]
. It is safe for upto 52 weeks. Exacerbation of psoriasis 
occurred in 10-15% of patients and disappeared after discontinuation of 
treatment. Tacalcital ointment is the least irritating agent. 
PHOTOCHEMOTHERAPY  
History  
              Phototherapy is the use of ultraviolet light for skin disorders. The 
treatment for skin diosorders used from 1400 BC in India 
[49]
. Psoralen is 
found in plants (lemon, lime, fig gloves, bergamot, babache) 
[50]
. 8 
methoxy psoralen & 5 methoxy psoralen are natural psoralens.  8 MOP is 
derived from the plant Ammi Majus. 5 MOP is derived from   
  
psoralea corylifolia. 4, 5, 8 Trimethyl psoralen, 3 Carbethoxy psoralen are 
synthetic psoralens.  
             In 1903 Nobel Prize was awarded to Niels Finsen for the 
treatment of lupus vulgaris by UV irradiation 
[51]
. In USA FDA gave 
approval for PUVA therapy in 1982. In 1976 Fisher, reported on the 
action spectrum for psoriasis. Combined use of psoralen with long wave 
UV irradiation is called as psoralen photo chemotherapy. In 1972 
Mortazawi developed oral PUVA therapy for psoriasis. It was 
popularized in 1974 by Parrish and Fitzpatrick et al 
[52]
. PUVA with 
topical psoralen was introduced in 1975 by Mortazawi and Obertse-Lehn. 
Bath PUVA was developed in 1977 by Born. 
               Psoralens are tricyclic  furocoumarins derived from plants. 8-
MOP and 5-MOP are currently available oral preparations which contain 
either crystals, micronized crystals or solubilized psoralens. Oral dosage 
8 methoxy psoralen 0.6mg/kg given one and half hours before irradiation. 
Its absorbtion is decreased by fatty meal. It will be active upto 8 -12 
hours.  
              High intensity fluorescent UVA tubes are used. UVA dose is 
increased 0.5-1.5J/cm2 per sitting.  If psoriasis clears after therapy PUVA 
will be stopped.   
  
UVA spectrum ranges from 320-400nm.UVA radiation penetrate 
the epidermis, papillary dermis & superficial vascular plexus. After 
radiation topical sunscreen should be given to all patients. 
PSORALEN CHEMICAL STRUCTURE  
 
Principle  
             UV radiation is produced artificially by following mechanisms. 
Electric current is passed through a gas ( mercury) ---> mercury atoms 
excited by passing electrons through the lamp’s electrode ---> It releases 
energy and they are absorbed as optical radiation (UV rays) 
LAMPS 
[53]
  
1. Fluorescent lamp 
2. Metal halide lamp (high pressure) 
3. Discharge lamp 
4. Conventional incandescent lamp 
  
5. Halogen incandescent lamp 
6.Mercury vapour lamp ( low pressure & high pressure mercury lamp, 
low pressure & high pressure sodium lamp, high pressure xenon lamp, 
high pressure krypton lamp, metal vapour lamp) 
7. Xenon short arc lamp 
ULTRAVIOLET LIGHT  
The wavelength of the ultraviolet light ranges from 200-400nm. 
UVC (germicidal reaction - 200-290 nm): It does not reach the earth’s 
surface because it is absorbed by ozone layer. It can penetrate upto 
reticular dermis. 
UVB (sunburn spectrum – 290-320):  Most of the sunscreens are used 
against this spectrum. It can penetrate upto papillary dermis. 
UVA (black light): It can penetrate the epidermal layer. 
           UVA1: 340-400 nm. 
          UVA2: 320-340nm.It is more effective and more damaging to 
normal skin. 
 
 
  
Precautions & Advice  
                Protect the eyes with goggles, face with a pillow case and male 
genitals with an athletic support. Sunlight exposure should be avoided 
eight hours after radiation. Sunscreen should be given after radiation.  
UV RADIATION DOSIMETRY  
                   The exposure dose (J/cm2) is calculated from irradiance and 
exposure time. Exposure dose = Irradiance × exposure time. 
The basic unit of power is watt. Watt=Joules/second 
Joule is the basic unit of energy. 
Irradiance is the power delivered per unit area of surface (W/cm2). 
MINIMAL PHOTOTOXIC DOSE  
              Lowest dose of UVA that causes erythema (grade1) 72 hours 
after exposure to UVA. Minimal phototoxic dose is measured by using an 
automated skin testing UVA irradiation unit. It is very difficult to 
calculate on Indian skin. 
 
 
 
  
GRADING OF ERYTHEMA  
Grade 0 – No erythema 
1 – Minimal erythema (pink colour) 
2 – Marked erythema (red colour) 
3 – Erythema and edema (fiery red) 
4 - Erythema, edema and blister (fiery red) 
MECHANISM OF ACTION 
[54, 55] 
    
 It has three steps. 
1. Psoralen binds with DNA double strand before irradiation 
[56-58]
. 
2. After UVA exposure bind with pyrimidine base to form cyclobutane 
monoadducts(MA). 
3. After absorbing a second photon, psoralen-DNA crosslink is formed by 
4MA.The reactive oxygen species are formed by this cross link, it 
damages cell membrane. This cross link inhibits DNA replication causing 
cell cycle arrest. So there is alteration of cytokine & cytokine receptor 
which causes apoptosis of lymphocytes & keratinocytes. 
 
  
PHASES OF PUVA THERAPY  
Clearing phase : The clearing phase starts with the 
commencement of therapy and ends with clearance of at least 95% of 
lesions. 
Maintenance phase :  It stars after 95% clearance of lesion. The 
final clearance dose of irradiation is constant and the frequency of 
treatment is gradually tapered.  
Tapering dose : 
                                          Weekly once 
                                                  Then, 
                                          Two weeks once   
                                                  Then, 
                                      Three weeks once 
                                                  Then, 
                                        Four weeks once  
                                                   Then, 
                                       Stop treatment 
[77, 78]
           
                                                    
  
TYPES OF PSORALEN 
1) Natural – 8 Methoxy psoralen  (8 MOP) 
                    5 Methoxy psoralen  (5 MOP)  
2) Synthetic - 4, 5, 8, Trimethyl psoralen 
                          carbethoxy psoralen (3 CP) 
[59,60] 
INDICATIONS FOR PHOTOCHEMOTHERAPY 
[62-65]
  
1. Psoriasis 
2. Vitiligo 
3. Atopic dermatitis 
4. Seborrhoeic dermatitis 
5. Alopecia areata 
6. Pityriasis rubra pilaris 
7. Lichen nitidus 
8. Urticaria pigmentosa 
9. Actinic prurigo 
10 .Pityriasis lichenoides 
11. Mycosis fungoides 
  
12. Langerhans cell histiocytosis 
13. Lymphomatoid papulosis 
CONTRAINDICATIONS 
[66]
  
1. Previos exposure to inorganic arsenic & radiotherapy 
2. H/O cutaneous malignancy 
 3. Genodermatoses like xeroderma pigmentosum and Blooms syndrome 
 4. Lupus erythematosus 
 5. Pemphigus vulgaris and bullous pemphigoid 
6. Pregnancy and lactation 
7. Children ≤ 18 years 
8. Previous cumulative therapy (>2000J/cm2)  
9. Pustular and erythrodermic psoriasis 
10. Liver and kidney failure 
11. Cardiac dysfunction 
12. Cataract 
 
  
CARCINOGENIC EFFECTS  
                  UVA radiation can aggravate the skin tumors in patients with 
xeroderma pigmentosum and  basal cell nevus syndrome. 
 SYSTEMIC PSORALENS 
The available systemic psoralens are 
8 Methoxy psoralen   
5  Methoxy psoralen – it has less gastrointestinal side effect. 
Trimethyl psoralen 
3-carbethoxy psoralen 
ORAL PUVA  
                 8-MOP– It is given one and half hours before UVA 2-3 
times/week. The dose is calculated according to patient body weight 
0.8mg/kg. Single capsule contains 10mg. 
                  5-MOP (1.2mg/kg) – It is given 2 hrs before UVA. 
 
 
 
  
ADVERSE EFFECTS 
[63]
 
SHORT TERM EFFECTS  
a) Adverse effects due to psoralen  
         Nausea, vomiting, headache, dizziness, bronchoconstriction, drug 
fever and hepatotoxicity. 
b) Phototoxic effect  
 Erythema, pruritus , pain, photo onycholysis, phytophoto dermatitis , 
blistering on hands and feet. 
      c)  Others  
 Hypertrichosis,  acneiform eruptions,  bullous pemphigoid and  
subungual haemorrhage of finger nails. 
LONG TERM EFFECT 
[59]
 
Chronic actinic damage,melanoma , squamous cell carcinoma and 
cataract. 
TOPICAL PUVA THERAPY   
1) BATH PUVA  
                    Trimethyl psoralen with UVA phototherapy was pioneered in 
Finland & Sweden. Synthetic furocoumarin 4, 5, 8-trimethyl psoralen is 
  
used for bath PUVA. 50 mg dissolved in 100 ml of ethanol and mixed in 
150 L of water at body temperature 
[67]
. 
2 )SOAK PUVA  
                      To avoid the side effects of systemic PUVA topical PUVA 
is useful. It has shown good results. Hand and/or foot soak in 8MOP 2.5 
mg/l for 15 minutes followed by UVA irradiation weekly two or three 
times is effective. 1 ml contains 5 mg of 8 MOP 
[67]
. In the literature there 
is no specific data regarding the initial dose of UVA irradiation for 
palmoplantar psoriasis. It depends upon the severity of the disease and 
higher UVA doses are recommended to treat the thicker skin of 
palmoplantar psoriasis 
[68]
. 
It is not associated with gastro intestinal tract and carcinogenic 
effects. Moisturization is needed before phototherapy in elderly 
populations because phototherapy itself can aggravate xerosis and 
pruritus 
[69]
. The emollients will decrease the total UVA dose required to 
clear psoriasis 
[61.70]
. Alternatively 5mg Trimethylpsoralen (TMP) in 10 
ml of ethanol can be used and mixed in 15 litres of water. 
 
 
 
  
8-METHOXY PSORALEN CHEMICAL STRUCTURE  
  
OTHER FORMULATIONS 
Cream and gel formulations (0.005% solution of aqueous 8-MOP 
gel) applied over the affected site for 15 minutes followed by UVA 
exposure 2 hours later. TMP bath UVA can be combined with oral 
etretinate or acitretin. The risk of skin cancer is less with topical PUVA 
than systemic PUVA. The dose of UVA is 15-20 times lower with bath 
PUVA. Bath PUVA with 8 MOP (2.6-3.7mg/l) is also successful. Bath 
temperature is 37°c and bath time is 15 minutes. 
OTHER TOPICAL COMBINATIONS WITH PUVA  
              Emollients will decrease the minimal phototoxic dose. 
Keratolytics should be given after phototherapy. Because it increases the 
minimal phototoxic dose.  Patient dislikes like anthralin with PUVA, 
because it stains the clothes. Vitamin D analogues and tazarotene 
  
decrease the duration of therapy and number of visits. For rapid clearance 
corticosteroids are useful. 
CONTRAINDICATED COMBINATIONS   
               Acitretin with cyclosporine should not be given. Acitretin 
inhibits cytochrome p450. So cyclosporine level will be increased 
[71, 74]
. 
Cyclosporine with PUVA combinations will increase the risk for 
squamous cell carcinoma either simultaneously or sequentially 
[72, 73]
. Tar 
with PUVA both will cause Phototoxicity. Methotrexate with 
cyclosporine both are immunosuppressants.  
 
 
 
 
 
 
 
 
 
  
                          MATERIALS AND METHODS 
STUDY DESIGN  
                  Prospective randomized control study. 
TOTAL POPULATION  
                 50 
STUDY PERIOD 
             The treatment duration was six months and the follow up period 
was six months. 
COLLECTION OF DATA AND SOURCES  
1. The study was conducted in Coimbatore medical college 
Hospital from December 2011 to November 2012. 
2. The population for the study included patients attending 
outpatient Department of Dermatology, Coimbatore Medical 
College Hospital, Coimbatore. 
3. The results were tabulated and appropriate tests of significance 
were worked up. 
 
 
 
  
INCLUSION CRITERIA    
1. Patients aged between 18-60 years. 
2. Patients who have not used other forms of topical treatment 
during the previous four weeks. 
3. Patients who have given written consent. 
EXCLUSION CRITERIA  
1. Age less than 18 years. 
2. Pregnant and lactating women. 
3. Patients who have not given consent. 
4. Concurrent immunosuppressive therapy and premalignant 
skin disease. 
5. Significant hepatic and renal dysfunction. 
6. Hypertensive  and diabetic patients. 
 
 
 
 
 
  
PATIENT EVALUATION 
                  History  
                 General examination 
                 Systemic examination 
                 Dermatological examination 
                 Laboratory investigations 
a) Complete blood count 
b) Urine routine 
c) Biopsy  
TREATMENT PROTOCOL  
  Patients under inclusion criteria were arranged randomly into two 
groups A and B. 
GROUP A 
 25 patients were included in this group. 0.5 ml of 1% 8 
Methoxypsoralen lotion was diluted in two litres of water. Hands and feet 
were soaked in that solution for 15 minutes. Then patient was advised to 
mop both palms and soles and to apply emollients followed by UVA 
exposure, 30 minutes after soak. Initial dose of UVA is 1 J/cm
2 
with 
  
increment dose of 0.5 J/cm
2  
 on every visit with a frequency of two times 
per week for six months. Eyes were protected by using goggles during 
treatment. 
GROUP B 
  25 patients were included in this group. Sequential therapy of 
0.05% Clobetasol propionate ointment with 0.005% Calcipotriol ointment 
was given for six months. 
PHASE 1: combination of clobetasol propionate and calcipotriol ointment 
once a day application in the first month. 
PHASE 2: clobetasol propionate for weekends and calcipotriol for week 
days once a day application in the second and third month. 
PHASE 3: calcipotriol ointment once a day application in the fourth, fifth 
and sixth month. 
TREATMENT ASSESMENT 
               Severity and extent of disease were calculated by using 
“Psoriasis Area Severity Index score” (PASI Score) and PASI percentage 
reduction score. PASI score was calculated before treatment, at the end of 
8
th
 week, 16
th
 week and 24
th
 week. 
 
  
 PASI score for Palmoplantar psoriasis  
                PASI = 0.2 (EU + IU + DU) AU + 0.4 (EL + IL + DL) AL 
             Area of Psoriatic involvement for Palms and Soles were 
calculated as 1. It means 10% of area was involved. Severity of 
Erythema, Induration, Desqumation was calculated as follows 0 – None, 
1 – Slight, 2 – Moderate, 3 – Severe, 4 – Very Severe.  
 
 
 
 
 
 
 
 
 
 
 
 AGE DISTRIBUTION 
        In Group A the 
years SD. In Group B the 
39.12±14.12 SD. 
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range of mean age in this study was 43.32 ± 15.70
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GROUP MEAN AGE  
(YEARS) 
A 43.32 
B 39.12 
 
Table No.2   MEAN AGE DISTRIBUTION 
 
 
                          Chart No.2   MEAN AGE DISTRIBUTION 
 
SEX DISTRIBUTION 
               In group A76 % patients were males, 24 % patients were 
females. In Group B 60 % patients were males, 40 % patients were 
females.  
               The overall male to female ratio was 34:16 (68%: 32%). 
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GROUP MALES FEMALES 
A 76% 24% 
B 60% 40% 
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DURATION OF DISEASE 
                    In Group A the range of mean duration of the disease in this 
study was 17.24±12.20 months SD. In Group B the range of mean 
duration was 17.08±14.67 months SD. 
GROUP MEAN DURATION 
(MONTHS) 
A 17.24 
B 17.08 
                    
Table No. 4   MEAN DURATION OF DISEASE 
 
 
Chart No.5 
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PASI REDUCTION SCORE 
                     According to graph the mean PASI score before treatment 
for Group A and Group B were 3.4 and 3.1 respectively. After eight 
weeks of treatment the mean PASI score for both Groups were 2.7 and 
2.2 respectively. After sixteen weeks of treatment the mean PASI score 
for both groups were 2.1 and 1.5 respectively. After twenty four weeks of 
treatment the mean PASI score for both groups were 1.4 and 0.9 
respectively. 
GROUP 
PASI SCORE 
BEFORE 
TREATMENT 
8 WKS 16 WKS 24 WKS 
A 3.4 2.7 2.1 1.4 
B 3.1 2.2 1.5 0.9 
 
Table No.5 PASI REDUCTION SCORE 
 
 
 
                                                  
 
 
 
Graph No.1 
  
PASI PERCENTAGE REDUCTION 
              From the graph after eight weeks of treatment the mean PASI 
percentage reduction for both groups were 21.28% and 29.55% 
respectively. After sixteen weeks of treatment the mean PASI percentage 
reduction for both groups were 40.66% and 50.56% respectively. After 
twenty four weeks of treatment the mean PASI percentage reduction for 
both groups were 60.50% and 70.77% respectively. 
                       
Table No.6  PASI PERCENTAGE REDUCTION 
DURINGTREATMENT 
 
Graph No.2 
       GROUP PASI PERCENTAGE REDUCTION 
 8 WEEKS 16  WEEKS 24 WEEKS 
A 21.28% 40.66% 60.50% 
B 29.55% 50.56% 70.77% 
  
SL.NO 
PASI PERCENTAGE(%) 
REDUCTION 
AT THE END OF 
TREATMENT 
GROUP A GROUP B 
1 10-20 - - 
2 21-30 - - 
3 31-40 - - 
4 41-50 4 2 
5 51-60 8 2 
6 61-70 7 4 
7 71-80 3 11 
8 81-90 - 5 
 TOTAL 22 24 
Table No.7  PASI PERCENTAGE REDUCTION AT THE END OF       
TREATMENT IN PALMOPLANTAR  PSORIASIS  
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ADVERSE EFFECTS 
  GROUP A 
                   Four patients (18.18%) developed adverse effects during 
treatment. Two patients developed erythema over palms and soles, two 
patients developed burning sensation.   
GROUP B 
                Three patients (12.5%) developed adverse effects during 
treatment. One patient developed erythema over soles and two patients 
developed itching and burning sensation over soles.   
GROUP ADVERSE EFFECT 
A 4 Patients (18.18%) 
B 3 Patients (12.5%) 
                                 
Table No.8 ADVERSE EFFECTS 
 
 
 
Chart No.7 
0
2
4
6
8
10
12
14
16
18
20
Group A Group B
P
e
rc
e
n
ta
g
e
PERCENTAGE OF ADVERSE EFFECTS 
Group A
Group B
  
STATISTICAL DATA ANALYSIS 
               Out of 25 patients selected for group A and group B, 22 patients 
came for treatment till twenty four weeks in group A, 24 patients came 
for treatment till twenty four weeks in group B. Only those patients were 
included for analysis. 
             76% of patients in group A were males, remaining 24% patients 
were females. In group B 60% patients were males, remaining 40% 
patients were females. Average age of group A patients were 
43.32±15.70 years SD. Average age of group B patients were 
39.12±14.12years SD. Average duration of disease in group A patients 
were 17.24±12.20 months SD. Average duration of disease in group B 
patients were 17.08±14.67 months SD. However Chisquare test did not 
show any significant association (X 
2
 =0.827  P>0.05) between groups 
and genders. 
              The average initial PASI score before treatment for group A was 
3.35±1.13 SD, for group B was 3.08±1.36 SD. The t test results did not 
show any significant difference in the average initial score between group 
A and group B. ( t value =0.753 P>0.05) 
 
 
  
Analysis of group A  
The initial score was compared with eighth week score for group 
A. It was found that the initial score was 3.3545 before treatment and it 
reduced to 2.67 with an average reduction in the score being 0.6818 and 
percentage reduction was 21.28%. 
 
The t test result showed significant 
difference at eighth week. (t value = 10.035 P<0.01) 
   At the end of sixteenth week it reduced to 2.0545 with an average 
reduction in the score being 1.300 and percentage reduction was 40.06%. 
The t test result showed significant difference at sixteenth week. (t value 
=12.889 P<0.01)   
At the end of twenty fourth week it reduced to 1.3727 with an 
average reduction in the score being 1.9818 and percentage reduction was 
60.50%. The t test showed significant difference at twenty fourth week. ( 
t value = 13.754 P<0.01) 
      Paired sample t test conducted for group A comparing initial scores 
with scores at eighth, sixteenth, twenty fourth week showed significant 
reduction in the scores at all three periods. 
 
 
  
Analysis of group B  
         The initial score was compared with eighth week score for group B. 
It was found that the initial score was 3.0750 before treatment and it 
reduced to 2.1583 with an average reduction in the score being 0.9167 
and percentage reduction was 29.55%. The t test showed significant 
difference at eighth week. (t = 8.571 P<0.01) 
          At the end of sixteenth week it reduced to 1.5083 with an average 
reduction in the score being 1.5667 and percentage reduction was 
50.56%. The t test showed significant difference at sixteenth week.   
(t = 9.603  P<0.01) 
             At the end of twenty fourth week it reduced to 0.8583 with an 
average reduction in the score being 2.2167 and percentage reduction was 
70.77%. The t test showed significant difference at twenty fourth week. 
(t=9.843 P<0.01) 
Paired sample t test conducted for group B comparing initial scores 
with scores at eighth, sixteenth, twenty fourth week showed significant 
reduction in the scores at all three periods. 
 
 
  
Analysis of both group A and group B  
   Comparison of percentage reduction for group A and group B at 
eighth week showed the group A patients had an average reduction of 
21.28%±9.30 SD. Whereas group B patients had an average reduction of 
29.55%±11.83SD. The t test showed significant difference in the 
percentage reduction in the scores between group A and group B at eighth 
week. (p<0.01) 
At sixteenth week group A patients had an average reduction of 
40.06±10.90 SD. Whereas group B patients had an average reduction of 
50.56±10.74 SD. The t test showed significant difference in the 
percentage reduction in the scores between group A and group B. 
(p<0.05) 
    At twenty fourth week group A patients had an average reduction 
of 60.50±10.26 SD. Whereas group B patients had an average reduction 
of 70.77±10.66 SD. Here the t test showed significant difference in the 
percentage reduction in the scores between group A and group B. 
(p<0.05) 
 
 
  
  Mean S.D t Value P Value 
Pair 1 
(After 8 
Weeks) 
A 21.28 9.30 
 
2.618 
 
P<0.01 
B 29.55 11.83 
Pair 2 
(After 16 
Weeks) 
A 40.06 10.90 
 
3.288 
 
P<0.05 
B 50.56 10.74 
Pair 3 
After (24 
Weeks) 
A 60.50 10.26 
 
3.324 
 
P<0.05 
B 70.77 10.66 
 
 Table No.9  PAIRED SAMPLE STATISTICS TABLE FOR PASI 
PERCENTAGE REDUCTION 
 
 
 
 
 
 
  
RESULTS 
GROUP A 
           Out of 22 patients, 20 (90%) showed more than 50% reduction of 
PASI score. None of the patient showed complete clearance of both 
palmar and plantar psoriasis. Four patients showed complete clearance of 
lesion in the palms. Two patients showed complete clearance of lesion in 
the soles. The average period of clearance of lesions was at 19 weeks. In 
six months follow up period 3 patients showed relapse after 15 weeks of 
average period of remission. 
GROUP B 
           Out of 24 patients, all patients (100%) showed more than 50% 
reduction of PASI score. Here also none of the patient showed complete 
clearance of both palmar and plantar psoriasis. Seven patients showed 
complete clearance of lesion in the palms and five patients showed 
complete clearance of lesion in the soles. The average period of clearance 
of lesions was at 20.3 weeks. In six months follow up period 2 patients 
showed relapse after 20 weeks of average period of remission. 
 
 
  
S.No Remission (weeks) Relapse (weeks) 
Group A Group B Group A Group B 
P PL P PL P     PL P PL 
1 17 - 22 - - - - - 
2 16 - 23 - - - - - 
3 20 - 19 - - - - - 
4 18 - 17 - 13 - - - 
5 - 22 16 - - 20 - - 
6 - 21 20 - - 12 - - 
7 - - 15 - - - - - 
8 - - - 24 - - - - 
9 - - - 22 - - - 20 
10 - - - 21 - - - - 
11 - - - 20 - - - - 
12 - - - 24 - - - 20 
                               
Table No.10  REMISSION AND RELAPSE 
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Image No.2 PUVA THERAPY 
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Image No. 3 PUVA THERAPY 
BEFORE TREATMENT 
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Image No.4  PUVA THERAPY 
BEFORE TREATMENT 
17 WEEKS AFTER TREATMENT 
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5  CALCIPOTRIOL COMBINATIONS
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BEFORE TREATMENT 
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DISCUSSION 
In our study on the treatment of palmoplantar psoriasis with topical 
PUVA therapy and sequential treatment with topical calcipotriol and 
clobetasol ointment, the mean age of the patients presented with 
palmoplantar psoriasis was 43.32 year. 68% of patients were males and 
32% were females and the mean duration of the disease was 17 months. 
Response to treatment were assessed based on reduction in PASI score 
and its percentage at 8
th
, 16
th
and 24
th
 week. 
TOPICAL PUVA (GROUP A) 
The starting dose of UVA therapy was 1J/cm
2 
with an increment of 
0.5 J/cm
2  
on subsequent visit. The maximum dose reached was 24.5 
J/cm2 for some patients. In our study, the group A patients treated with 8 
methoxypsoralen solution along with ultraviolet A therapy twice weekly 
showed reduction in PASI score of 21.28%, 40.66%, 60.50% at the end 
of 8
th
, 16
th
and 24
th
 respectively. Maximum improvement was observed at 
24
th
 week. 
There are many studies in literature about the topical PUVA in the 
treatment of palmoplantar psoriasis, but the results were not consistent. 
Various studies conducted for the treatment of palmoplantar psoriasis are 
  
1. Wilkinson JD Ralfs IG et al, in this study 67% of patients showed 
considerable improvement with topical application of methoxypsoralen 
along with UVA 
[75]
.  
2. Abel EA et al, in this study five (35.7%) out of 14 patients had 
complete clearance of lesions after 15 to 40 treatments 
[76]
. 
3. Norbert J. Neumann et al, showed 64.64% reduction of  PASI 
score
[86]
.  
4. Tsankov N et al, this study showed 40% of patients had marked 
improvement after 15 sessions of  PUVA therapy 
[84]
. 
5. Petty A et al, reported the most commonly used therapeutic options 
for palmo-plantar psoriasis are long-term treatment with topical 
corticosteroids and hand foot PUVA, but the  disease become resistant to 
these  modalities  after sometime 
[85]
 . 
6. Tsankov N et al, showed no statistically significant difference between 
the combination of calcipotriol with UVA phototherapy and PUVA  in 
regard to the therapeutic effect 
[84]
 . 
 In our study for the treatment of palmoplantar psoriasis with 
PUVA therapy, 4 out of 22 patients (18.18%) had complete clearance of 
palmar psoriasis and 2 patients (9.09%) had complete clearance of plantar 
  
psoriasis after 34 to 44 treatment sessions. 18 % of patients developed 
adverse effect during treatment. In the follow up period, 3 patients 
developed relapse after 15 weeks of remission. These findings in our 
study are comparable to the above mentioned studies conducted for the 
treatment of palmoplantar psoriasis with PUVA therapy. 
 The disadvantages of PUVA are unavailability of PUVA chamber 
in many centers, repeated hospital visits and long term side effects. 
COMBINATION OF CALCIPOTRIOL WITH CLOBETASOL 
PROPIONATE OINTMENT (GROUP B) 
The topical  calcipotriol and  clobetasol propionate ointment was 
given in a sequential manner for 6 months. In this group maximum 
percentage reduction of PASI score was 29.55%, 50.56% and 70.77% at 
the end of 8
th
, 16
th
 and 24
th
 weeks respectively. The maximum 
improvement was observed at the end of 16
th
 and 24
th
 weeks. 
Studies related to the treatment of palmoplantar psoriasis with 
combination of topical calcipotriol and steroids were very less but many 
studies were done with combination of calcipotriol and steroids for the 
treatment of other type of psoriasis. 
These combinations showed better results for the treatment of 
localized plaque type of psoriasis. Eventhough the onset of action of 
  
calcipotriol is slow; steroid will trigger its action and reduces the irritant 
potential of calcipotriol. The advantage of calcipotriol is that it can be 
given safely for children, diabetic and hypertensive patients. 
In a randomized, double-blind  controlled trial  of  van der 
Vleuten CJ  et al 
[79]
 , 71.2% of patients achieved "absent" or "very mild" 
disease with the two-compound scalp formulation, compared to 64% with 
betamethasone dipropionate and 36.8% with calcipotriene  alone. But the 
disadvantage is pruritus in the combination 
[79, 80]
.  
The efficacy of occlusive topical calcipotriol therapy is better than 
nonocclusive therapy. The study by Duweb et al, showed better efficacy 
with  occlusive calcipotriol applied  for 6 weeks, twice-weekly occlusive 
calcipotriol ointment was as effective as the twice-daily application 
[81]
. 
        A study by Lebwohl M and Menter A et al , revealed that a high-
potency topical corticosteroid in combination with vitamin D analog gave 
better efficacy, although it does not appear to be as effective as super 
potent corticosteroid used alone 
[82,83]
. A combination with super potent 
topical clobetasol or halobetasol gave better results than with high potent 
topical betamethasone ointment. 
  
  In a similar study by Koo J, Blum RR and Lebwohl M (2006) et 
al with the combination of topical calcipotriol with clobetasol, there was 
a 92% clearance of skin lesions after 6 months of therapy 
[37]
.  
           In our study  16 patients (66.7%) showed more than 70% clearance 
of psoriatic skin lesions of both palms and soles after 6 months of therapy 
with topical calcipotriol and clobetasol with least side effects compared 
with 3 patients (13.6%) in PUVA therapy group.  
In group B Seven patients (29.16%) showed 100% clearance of 
palmar psoriasis and five patients (20.83%) showed 100% clearance of 
plantar psoriasis after six months of therapy, which is comparable with 
the study done by Koo J, Blum RR,Lebwohl M (2006) et al .  
 
 
 
 
 
 
 
  
 
CONCLUSION 
1. Efficacy of topical calcipotriol ointment and  steroid used in sequential 
manner is better than  the topical psoralen ultraviolet A therapy. 
2. All the patients (100%) in calcipotriol and steroid combination group 
showed more than 50% reduction of PASI score . But in PUVA 
therapy group  90% of patients showed more than 50% reduction of 
PASI score. 
3. On comparing the adverse effects , patients on PUVA therapy group 
developed more adverse effects than the patients on calcipotriol and 
steroid combination group .  
4. The duration of remission maintenance was long in calcipotriol and  
steroid combination  group when compared to PUVA therapy group. 
In our study, we arrived at the conclusion  that topical therapies 
used in a sequential manner  was more effective and it may be considered 
as a first line therapy for the treatment of patients with palmoplantar 
psoriasis.  
 
 
   
 
 
  
PROFORMA FOR PALMOPLANTAR PSORIASIS 
TITLE OF THE STUDY : Comparative study of efficacy of hand 
foot psoralen ultraviolet A therapy versus sequential therapy of topical 
clobetasol propionate with topical calcipotriol ointment in palmoplantar 
psoriasis 
NAME:                                                                                                        
AGE/SEX:                                                                                                      
DATE: 
OCCUPATION: 
ADDRESS: 
PHONE NO: 
PRESENT HISTORY: 
a) DURATION : 
b) SYMPTOMS : 
PAST HISTORY: 
TREATMENT HISTORY: 
FAMILY HISTORY: 
  
 
GENERAL EXAMINATION: 
               BP :               PR :                        FOCAL INFECTIONS : 
SYSTEMIC EXAMINATION : 
              CVS :                            RS: 
INVESTIGATIONS : 
             CBC :                                                             RFT : 
             RBS :                                                             LFT : 
SERUM ELECTROLYTES : 
BIOPSY : 
FOLLOW UP : (PASI SCORE) 
 BEFORE TREATMENT           8WEEKS                        16 WEEKS                             
24WEEKS 
PASI PERCENTAGE REDUCTION : 
         8 WEEKS                       16 WEEKS                         24 WEEKS 
SIDE EFFECTS : 
        ERYTHEMA/IRRITATION :                                   OTHERS :      
  
CONSENT FORM 
Yourself Mr./Mrs./Ms………………………………..  are being 
asked to be a participant in the research study titled ““ Comparative study 
of efficacy of hand foot psoralen ultraviolet A therapy versus sequential 
therapy of topical clobetasol propionate with topical calcipotriol ointment 
in palmo plantar psoriasis ””in CMC Hospital, Coimbatore, conducted by  
Dr.P.ABIRAMI, Post Graduate Student, Department of Dermatology, 
Venerology and Leprosy,  Coimbatore Medical College Hospital. You are 
eligible after looking into the inclusion criteria. You can ask any question 
you may have before agreeing to participate. 
Research Being Done 
 At Outpatient Department of  Dermatology  Coimbatore Medical 
College Hospital, Coimbatore. 
Purpose of Research 
To observe the efficacy and side effect of Psoralen ultra violet A 
therapy and combination treatment of topical clobetasol propionate with 
Calcipotriol ointment 
 
 
  
Decline from Participation 
You have the option to decline from participation in the study  
existing  protocol for your condition. 
Privacy and Confidentiality 
Privacy of individuals will be respected and any information about 
you or provided by you during the study will be kept strictly confidential. 
Authorization to publish Results   
Results of the study may be published for scientific purposes 
and/or presented to scientific groups; however you will not be identified. 
Statement of Consent 
I volunteer and consent to participate in this study. I have read the 
consent or it has been read to me. The study has been fully explained to 
me in my own language, and I may ask questions at any time. 
-------------------------------                           -------------------------------   
Signature /Left thumb impression                       Date 
(Volunteer)   
--------------------------------                          -------------------------------- 
Signature of witness                                               Date 
  
ABBREVIATIONS 
IL  –  Interleukin 
IFN  –  Interferon 
ICAM –  InterCellular Adheshion Molecule  
TNF  –  Tumor Necrosis Factor 
PASI  –  Psoriasis Area Severity Index 
UVA  – Ultraviolet A 
FDA  – Food and Drug Administration 
RXR  – Retinoid Receptor X [Rexinoid] 
GM – CSF –  Granulocyte Monocyte Colony Stimulating Factor 
Th1, Th2 –  Helper T cell 1, 2 
CD  –  Cluster Differentiation 
TCS  –  Topical Corticosteroids 
MOP  –  Methoxypsoralen 
MA  –  Monoadducts 
TMP  –  Trimethoxypsoralen 
GIT  –  Gastrointestinal Tract 
RePUVA  –  Retinoid with PUVA 
P  –  Palmar 
PL   – Plantar 
SD                _        Standard Deviation 
    
  
MASTER CHART 
S.NO 
AGE 
(YRS) 
SEX 
M/F 
DURATION 
(MTH) 
PASI SCORE (WKS) PASI % RED (WKS) AE REMISSION (WKS ) 
RELAPSE 
(WKS) 
    
BT 8 16 24 8 16 24 
   
1 32 F 24 3.8 3 2.4 1.4 21.05 36.84 63.16 N 
  
2 36 M 7 3 2.6 1.8 1.2 13.33 40 60 N 
  
3 26 M 48 4 2.6 2 0.8 35 50 80 N 17(P) 
 
4 40 M 18 2.8 2.6 1.6 1.4 7.14 42.86 50 N 
  
5 47 M 9 4 2.8 2.2 1.6 30 45 60 N 
  
6 59 M 8 2.6 2 1.6 0.8 23.08 38.46 69.23 N 16(P) 
 
7 64 M 30 4.4 3.8 2.8 2.2 13.64 36.36 50 N 
  
8 39 M 9 1 0.6 0.4 0.2 40 60 80 Y 22(PL) 20(PL) 
9 67 M 12 3 1.8 1.6 0.8 40 46.67 73.33 N 20(P) 
 
10 19 M 18 1.8 1.2 0.8 0.6 33.33 55.56 66.67 N 
  
11 55 M 7 2.4 1.8 1.2 0.8 25 50 66.67 Y 18(P) 13(P) 
12 38 M 9 3.8 - - - - - - N 
  
13 50 M 9 3.6 3 2.8 2 16.67 22.22 44.44 N 
  
14 28 F 7 1.8 1.6 1.4 0.6 11.11 22.22 66.67 N 21(PL) 12(PL) 
15 54 M 6 3.6 3 2.4 1.6 16.67 33.33 55.56 Y 
  
16 42 M 11 2.4 1.8 1.2 1 25 50 58.33 N 
  
17 60 F 36 4.4 3.6 3 2 18.18 31.82 54.55 N 
  
18 20 M 24 6 4.8 3.6 2.2 20 40 63.33 N 
  
19 53 M 6 3.8 3.2 3 1.8 15.79 21.05 52.63 N 
  
20 30 M 36 5 4.2 3.2 2.4 16 36 52 N 
  
21 62 F 7 3.2 - - - - - - N 
  
22 46 M 12 3.6 3 3.6 1.6 16.67 50 55.56 N 
  
23 70 M 30 3.8 3.4 3.8 2.2 10.53 26.32 42.11 Y 
  
              
              
  
  
  
KEY TO MASTER CHART 
1 - 25    -  GROUP A 
26 – 50  -  GROUP B 
12, 21, 24, 48  –  LOST FOLLOW UP 
YRS    –  YEARS 
M/F   –  MALE/FEMALE 
MTH   –  MONTHS 
PASI   –  PSORIASIS AREA SEVERITY INDEX 
WKS   –  WEEKS 
BT   –  BEFORE TREATMENT 
RED    –  REDUCTION 
AE   –  ADVERSE EFFECTS 
N    –  NO 
Y   –  YES 
P   –  PALMAR 
PL    –  PLANTAR 
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